CHI Advisors LLC - Q2 2023 holdings

$330 Million is the total value of CHI Advisors LLC's 26 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 0.0% .

 Value Shares↓ Weighting
CMPX  COMPASS THERAPEUTICS INC$8,998,484
-2.8%
2,829,7120.0%2.73%
+11.2%
 OMEGA THERAPEUTICS INC$5,912,938
-7.1%
1,055,8820.0%1.79%
+6.2%
OVID  OVID THERAPEUTICS INC$2,836,616
+27.1%
864,8220.0%0.86%
+45.4%
 SYROS PHARMACEUTICALS INC$2,417,452
+18.0%
767,4450.0%0.73%
+34.9%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR/A filed 2023-08-22
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
PRECISION BIOSCIENCES INC17Q3 202313.4%
OVID THERAPEUTICS INC17Q3 20235.8%
CORVUS PHARMACEUTICALS INC16Q2 20231.8%
KEZAR LIFE SCIENCES INC15Q1 20235.8%
PLIANT THERAPEUTICS INC14Q3 202329.2%
REPARE THERAPEUTICS INC14Q3 202330.3%
ORCHARD THERAPEUTICS PLC14Q4 202252.6%
LARIMAR THERAPEUTICS INC14Q3 20239.1%
KEROS THERAPEUTICS INC14Q3 20238.6%
INOZYME PHARMA INC13Q3 20239.4%

View CHI Advisors LLC's complete holdings history.

Latest significant ownerships (13-D/G)
CHI Advisors LLC Q2 2023 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Corvus Pharmaceuticals, Inc.February 13, 20232,384,4025.1%
Cullinan Oncology, Inc.February 13, 20233,317,5447.2%
Freeline Therapeutics Holdings plcFebruary 13, 20234,814,4197.4%
Inozyme Pharma, Inc.February 13, 20232,204,8765.5%
Larimar Therapeutics, Inc.February 13, 20233,473,3668.0%
Oncorus, Inc.February 13, 20232,367,4369.1%
Orchard Therapeutics plcFebruary 13, 20237,987,3966.3%
PLIANT THERAPEUTICS, INC.February 13, 20233,199,8926.6%
Repare Therapeutics Inc.February 13, 20232,800,1266.7%
VectivBio Holding AGFebruary 13, 20235,492,8938.8%

View CHI Advisors LLC's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2023-11-13
13F-HR/A2023-08-22
13F-HR2023-08-11
13F-HR2023-05-11
SC 13G/A2023-02-13
SC 13G/A2023-02-13
SC 13G/A2023-02-13
SC 13G/A2023-02-13
SC 13G/A2023-02-13
SC 13G/A2023-02-13

View CHI Advisors LLC's complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported has been restated
  • The reported has been amended

Export CHI Advisors LLC's holdings